Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
What dose contraints do use for the pulmonary artery and vein when treating with a lung lesion with SBRT?
Related Questions
What are your top takeaways in Thoracic Cancers from ASTRO 2024?
Do you have different hotspot and heterogeneity goals for SBRT of ground glass lesions vs more solid adenocarcinoma NSCLC lesions?
How would you approach SBRT in a pacemaker-dependent elderly patient with Stage I NSCLC whose SBRT plan Dmax exceeds the pacemaker tolerance?
Would you consider delaying tarlatamab initiation in a patient with ES SCLC who recently completed RT for CNS disease, given the concern for immune effector cell-associated neurotoxicity syndrome (ICANS)?
Do you restrict the dose rate during treatment delivery to a pacemaker in addition to limiting the Dmax?
How would you treat a patient with newly diagnosed ALK+ Stage IIIB non-small cell lung cancer (NSCLC)?
Is there any role for adjuvant radiotherapy for resected multistation N2 atypical carcinoid tumor of the lung?
How do you construct your target volumes for superior sulcus tumors?
How do you approach a patient with stage IIA non-small cell lung cancer who received SBRT?
Would you offer consolidative radiotherapy for oligometastatic NSCLC?
